5 Key Takeaways

• 1

  The study developed a drug-regulated off-switch protein–protein interaction CAR (DROP-CAR) using human protein components.

• 2

  Venetoclax effectively disrupts the DROP-CAR configuration, leading to near-total receptor disassembly in Jurkat cells.

• 3

  DROP-CAR T cells showed reduced interferon-γ production and cytotoxicity when treated with venetoclax, unlike second-generation CAR T cells.

• 4

  Live-cell imaging revealed that venetoclax treatment impaired immune synapse formation and altered calcium flux in DROP-CAR T cells.

• 5

  The DROP-CAR system offers a clinically feasible method to modulate CAR-T cell activity using an existing cancer therapy.